Betamethasone microspheres

Drug Profile

Betamethasone microspheres

Alternative Names: Betamethasone DDS; DE-102

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Santen Pharmaceutical
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules; Steroids
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetic macular oedema; Retinal oedema

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 15 Jun 2015 No recent reports of development identified - Phase-II/III for Diabetic macular oedema in Japan (Injection)
  • 15 Jun 2015 No recent reports of development identified - Phase-II/III for Retinal oedema in Japan, South Korea (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top